<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927797</url>
  </required_header>
  <id_info>
    <org_study_id>L-278/2004</org_study_id>
    <secondary_id>BfArM 4022892</secondary_id>
    <nct_id>NCT00927797</nct_id>
  </id_info>
  <brief_title>Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)</brief_title>
  <acronym>PERLL</acronym>
  <official_title>Phase II Study to Evaluate the Safety and Efficacy of the Treatment With Pentostatin, Cyclophosphamide and Rituximab Followed by Rituximab Maintenance in Previously Untreated and Relapsed Patients With Immunocytoma/Morbus Waldenström, B-CLL and Other Indolent B-Cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Diakonie Krankenhaus Schwäbisch Hall, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum am Plattenwald, Bad Friedrichshall, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diakonieklinikum Stuttgart, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gemeinschaftspraxis Porowski &amp; Koniczek, Heilbronn, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of Fludarabine and Cyclophosphamide have yielded overall response rates of
      over 80% in previously untreated patients with indolent Non-Hodgkin-Lymphoma. However,
      hematotoxicity rates were high with Grade 3 and 4 toxicities of over 50%. Several studies
      have indicated that the treatment with Pentostatin and Cyclophosphamide causes lower
      hematotoxicity rates than the combination of Fludarabine and Cyclophosphamide. To evaluate
      the efficacy and safety of treatment with Pentostatin/Cyclophosphamide immuno-chemotherapy
      for patients with newly diagnosed or relapsed Immunocytoma/Morbus Waldenström, B-cell chronic
      lymphocytic leukemia (B-CLL) and other indolent CD20-positive B-NHL, an open, non-randomized,
      multi-center prospective phase II-study to evaluate the efficacy and safety of treatment with
      immuno-chemotherapy is conducted. Treatment consists of 6 courses of Pentostatin (4mg/m² on
      day 1), Cyclophosphamide (600mg/m² on day 1) and Rituximab (375mg/m² on day 0) administered
      every three weeks. Patients achieving complete or partial remission undergo maintenance
      therapy consisting of 8 courses of Rituximab (375mg/m²) administered every three months over
      a period of 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2005</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: overall response rate</measure>
    <time_frame>after 6 months and after 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to WHO-Grading</measure>
    <time_frame>throughout the treatment and until 36 months after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: complete remission rate</measure>
    <time_frame>after 6 months and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: partial remission rate</measure>
    <time_frame>after 6 months and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: progression-free survival</measure>
    <time_frame>after 6 months and 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Immunocytoma/Morbus Waldenström</condition>
  <condition>B-Cell Non-Hodgkin's Lymphoma</condition>
  <condition>B-Cell Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Immunochemotherapy, Maintencance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide, Pentostatin, Rituximab</intervention_name>
    <arm_group_label>Immunochemotherapy, Maintencance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed first diagnosis of or relapsed CD20-positive Immunocytoma, B-CLL or other
             indolent B-NHL

          -  therapy-requiring CLL defined as: Binet stage C or Binet B combined with occurence of
             B-symptoms, rapidly progressing disease, risk of organ compression by lymphoma mass

          -  therapy-requiring Immunocytoma as defined by the Consensus Panel Recommendations from
             the Second International Workshop on Waldenström´s Macroglobulinemia, 2003)

          -  age &gt; 18 years

          -  anticipated life expectancy &gt; 6 months

          -  ECOG 0-3

          -  no significant comorbidities

          -  signed informed consent

          -  efficient method of contraception during time of therapy (men and women)

        Exclusion Criteria:

          -  age &lt; 18 years

          -  CD20 negativity

          -  significant comorbidities interfering with therapy as required by the protocol

          -  history of HIV infection or active hepatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony D Ho, Ph.D., Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Department</affiliation>
  </overall_official>
  <link>
    <url>http://www.klinikum.uni-heidelberg.de</url>
    <description>Homepage of the Department</description>
  </link>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <last_update_submitted>June 24, 2009</last_update_submitted>
  <last_update_submitted_qc>June 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. A. D. Ho</name_title>
    <organization>University of Heidelberg</organization>
  </responsible_party>
  <keyword>immunochemotherapy</keyword>
  <keyword>Pentostatin</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Maintenance</keyword>
  <keyword>indolent B-NHL</keyword>
  <keyword>B-CLL</keyword>
  <keyword>B-NHL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Pentostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

